Dermatology
Soligenix's Platform Approach to Drug Development Offers Efficiency in Biopharmaceutical Innovation
Soligenix Inc. demonstrates how platform-based drug development using synthetic hypericin across multiple dermatologic conditions can streamline clinical impact and reduce redundancy in the biotech industry.
Soligenix Reports Positive Interim and Comparative Data for CTCL Treatment HyBryte
Soligenix announced consistent interim response rates from its phase 3 FLASH2 study and positive comparative results for HyBryte against Valchlor in cutaneous T-cell lymphoma, highlighting progress for a disease with limited treatment options.
Immune Cell Surface Sugar Shedding Identified as Key Factor in Psoriasis Progression
New research reveals immune cells shed surface sugars before entering inflamed skin in psoriasis patients, potentially opening new treatment pathways for the chronic autoimmune condition.
Soligenix Advances Psoriasis Treatment SGX302 with Promising Early Clinical Results
Soligenix is progressing its phase 2a clinical trial of SGX302 for psoriasis treatment, showing encouraging safety and biological activity data that positions the therapy to address a $67 billion global market opportunity.
Pelage Pharmaceuticals Raises $120 Million for Revolutionary Hair Growth Therapy
Pelage Pharmaceuticals secured $120 million in Series B funding to advance its novel regenerative hair growth therapy PP405, which could transform treatment for millions suffering from hair loss by reactivating dormant hair follicle stem cells.
Soligenix Strengthens Medical Advisory Board to Advance HyBryte CTCL Treatment Through Phase 3 Development
Soligenix has updated its U.S. Medical Advisory Board with leading dermatologic and oncologic experts to guide the Phase 3 development and potential commercialization of HyBryte, a novel photodynamic therapy for cutaneous T-cell lymphoma that addresses significant unmet medical needs.
Soligenix Advances Psoriasis Treatment Trial with Promising Early Results
Soligenix is progressing its SGX302 psoriasis treatment through clinical trials, offering potential for a new therapeutic option for millions affected by the autoimmune skin condition.
Stonegate Capital Partners Initiates Coverage on Medicus Pharma, Highlighting Strategic Pipeline Expansion
Investment firm Stonegate Capital Partners has initiated coverage on Medicus Pharma Ltd., emphasizing the company's strategic acquisitions and partnerships that position it for growth in dermatology and infectious disease treatments.
Viromed Medical AG Achieves ISO 13485 Certification, Clears Path for ViroCAP® Market Launch
Viromed Medical AG's ISO 13485 certification enables independent market entry for its ViroCAP® cold plasma medical devices, positioning the company for accelerated growth in dermatology and veterinary markets starting October 2025.
CALDRÉ Launches Ayurvedic Skincare Line for Babies and Sensitive Skin
CALDRÉ's new Ayurvedic skincare line addresses growing concerns about chemical-laden products by offering natural, dermatologist-tested solutions for babies and sensitive skin, expanding DesiNRI's family care legacy.
New Guide Helps Dermatology Practices Navigate 2025 Reimbursement Cuts
Inga Ellzey Billing Companies has released a resource to help dermatology clinics mitigate financial impacts from upcoming 2025 reimbursement cuts through proactive revenue protection strategies.
New Study Challenges Traditional Psoriasis Severity Classifications
Recent research indicates that psoriasis affecting less than 3% of body surface area may still impose a significant disease burden, prompting a reevaluation of current treatment approaches.
Austin's Skincare Renaissance: Embracing Radiance and Resilience in the Hill Country Heat
Austin's evolving skincare trends highlight a shift towards luxurious, protective products that nourish and defend against the harsh Texas sun, reflecting a broader cultural move towards self-care and vitality.
Scinai Immunotherapeutics Ltd. Announces Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has published peer-reviewed data in the Journal of Dermatological Treatment, highlighting PC111's potential as a disease modifier for pemphigus and SJS/TEN, offering a new, non-immunosuppressive treatment approach.
Dr. Anna Chacón Featured on Negocios Magazine Cover for Pioneering Telemedicine in Dermatology
Dr. Anna Chacón's feature on Negocios Magazine highlights her innovative telemedicine model that revolutionizes access to dermatological care across the U.S., showcasing her blend of medical expertise and entrepreneurial vision.
L-UV Revolutionizes Sun Care with Dermatologist-Tested SPF Brand
L-UV is transforming sun safety into a daily lifestyle choice with its dermatologist-tested, sensitive skin-friendly SPF products, emphasizing prevention and style.
AI Enhances Skin Cancer Diagnosis Accuracy, Study Finds
A collaborative study reveals artificial intelligence significantly improves the consistency and accuracy of skin cancer tissue analysis, offering better patient outcome predictions.
Image Protect, Inc. Unveils Strategic Growth Vision with InterceptCS™ Cold Sore Prevention System
Image Protect, Inc. outlines its strategic growth vision and long-term revenue objectives centered on the InterceptCS™ Cold Sore Prevention System, targeting a significant market opportunity in the wellness technology space.
Study Reveals Grapes May Enhance Skin's Resistance to UV Damage
Recent research highlights the potential of grapes to protect skin from UV damage, offering a natural approach to sun care alongside traditional methods.
Silicon Valley Aesthetic Dermatology Highlights Importance of Age-Appropriate Skin Care
Silicon Valley Aesthetic Dermatology's new blog post emphasizes the need for updating skin care routines as the body ages, offering insights into effective treatments and technologies.
Scinai Immunotherapeutics Ltd. Highlights PC111 Breakthrough Following Top Italian Dermatology Award
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) celebrates Dr. Roberta Lotti's award-winning research on PC111, a promising treatment for pemphigus vulgaris, underscoring its potential as a non-immunosuppressive therapy for autoimmune skin conditions.
Medicus Pharma Ltd. Develops Novel Non-Invasive Treatment for Basal Cell Carcinoma
Medicus Pharma Ltd. is advancing a revolutionary, non-invasive microneedle patch treatment for basal cell carcinoma, potentially transforming the $15 billion skin cancer treatment market.
Creative Biolabs Expands Skincare Innovation with Multi-source Exosome Research Line
Creative Biolabs introduces a groundbreaking multi-source exosome skincare research line, offering new avenues for anti-aging and regenerative skincare solutions.
Scientific Breakthrough in Anti-Aging: Key Ingredients Show Promise
Recent dermatological research highlights five key ingredients—Matrixyl, Argireline, Volufiline, Retinol, and PDRN—that offer significant anti-aging benefits, addressing wrinkles, skin volume loss, and cellular senescence with minimal irritation.
Study Reveals Unchanged Prevalence of Psoriasis in the U.S., Highlights Need for Better Treatments
A recent study published in the Journal of American Academy of Dermatology shows the prevalence of psoriasis among U.S. adults remains steady at 3% over the last decade, underscoring the ongoing need for effective treatments and improved diagnostic access.
MDPen Launches Corrective Microneedling™: Advanced Skin Rejuvenation Technology
MDPen introduces a cutting-edge microneedling technique that creates up to 324,000 microchannels per minute, offering comprehensive skin rejuvenation solutions for practitioners and patients across multiple skin concerns.
Study Reveals Link Between Ultra-Processed Foods and Psoriasis Risk
New research published in Nutrients journal suggests a significant correlation between ultra-processed food consumption and increased psoriasis risk, highlighting potential dietary implications for patient health.
Soligenix's HyBryte Shows Promising Results in CTCL Treatment, Offering New Hope for Rare Skin Cancer Patients
Biotechnology company Soligenix has reported impressive interim results for HyBryte, a novel topical treatment for cutaneous T-cell lymphoma (CTCL), demonstrating a 75% response rate and potential to address a significant unmet medical need.
Scinai Immunotherapeutics to Discuss Potential Breakthrough Treatment for Rare Skin Disorders
Scinai Immunotherapeutics will host a webinar to explore the therapeutic potential of PC111, a novel monoclonal antibody targeting rare skin conditions like Pemphigus Vulgaris and SJS/TEN, following its recent acquisition of Pincell.